SCHEMBL20633697

SCHEMBL20633697

O=C1NC(=S)NC12CCNCC2

nearest known ligand 0.39

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
NEK2 P51955 1/20 0.36
ALDH1A1 P00352 1/20 0.32
HTT P42858 1/20 0.32
PYGL P06737 2/20 0.31
PYGB P11216 1/20 0.31
PYGM P11217 1/20 0.31
CRBN Q96SW2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21371647 0.86
SCHEMBL18420875 0.82 ALDH1A1 (0.42) ALDH1A1HTT
SCHEMBL16868373 0.82 ALDH1A1 (0.47) ALDH1A1HTT
SCHEMBL23651597 0.80 ALDH1A1 (0.50) ALDH1A1HTT
SCHEMBL17082979 0.80 ALDH1A1 (0.50) ALDH1A1HTT
SCHEMBL239415 0.77 CRBN (0.41) NEK2CRBN
Ammonia Solution, Strong SCHEMBL1763719 0.76 CRBN (0.40) NEK2CRBN
Hydrochloric Acid SCHEMBL8809373 0.76 CRBN (0.40) NEK2CRBN
SCHEMBL24767075 0.71 LMNA (0.31)
SCHEMBL23651601 0.71 PDE7A (0.38) NEK2CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352366-B2 2-aminoquinazolinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-06-07 US disclosed
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-05-12 US disclosed
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-09 US disclosed
US-11066425-B1 Oxo-substituted compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-07-20 US disclosed
WO-2019009369-A1 IMINE DERIVATIVE 大日本住友製薬株式会社 2019-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066425-B1 Oxo-substituted compound CYP51A1, OXA1L, O60361 NEK2 2829/4885ALDH1A1 473/4885HTT 4871/4885
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, CRKL NEK2 993/4885ALDH1A1 645/4885HTT 2733/4885
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, SLC26A3 NEK2 733/4885ALDH1A1 739/4885HTT 2226/4885
US-11352366-B2 2-aminoquinazolinone derivative CNKSR1, HAX1, SLC26A3 NEK2 733/4885ALDH1A1 739/4885HTT 2226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.